Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.30
Bid: 1.30
Ask: 1.33
Change: -0.005 (-0.38%)
Spread: 0.03 (2.308%)
Open: 1.30
High: 1.30
Low: 1.29
Prev. Close: 1.32
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

5 Nov 2019 10:00

RNS Number : 3031S
RTW Venture Fund Limited
05 November 2019
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

RTW Venture Fund Limited

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Ducasse Group Limited

City and country of registered office (if applicable)

Road Town, Tortola, British Virgin Islands

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

30/10/2019

6. Date on which issuer notified (DD/MM/YYYY):

31/10/2019

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

11.37%

N/A

11.37%

161,544,695

Position of previous notification (if

applicable)

N/A

N/A

N/A

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GG00BKTRRM22

18,361,456

11.37%

SUBTOTAL 8. A

18,361,456

11.37%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

The Mountain Trust Company

Mari-Cha Investment Group Limited

Search Private Equity Holdings Limited

Search Private Equity II Limited

Ducasse Group Limited

11.37%

N/A

11.37%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Please note, the total amount of voting rights have been rounded to 2 decimal places therefore there is a possibility of a rounding error.Mountain Trust Company is the ultimate holding legal entity, which holds Mari-Cha Investment Group Limited, which in turns holds Search Private Equity Holdings Limited, which in turn holds Search Private Equity II Limited, which in turn holds Ducasse Group Limited.

General email contact: fundadminops@sailfunds.com

 

 

Place of completion

Hong Kong

Date of completion

31/10/2019

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUVVKRKBAARRA
Date   Source Headline
18th Jan 20247:00 amRNSTransaction in Own Shares
15th Jan 20247:00 amRNSMonthly Valuation Update, December Factsheet
10th Jan 20247:00 amRNSTransaction in Own Shares
8th Jan 20249:00 amRNSInvestment Update
5th Jan 20241:00 pmRNSPublication of a Prospectus
2nd Jan 20247:00 amRNSTotal Voting Rights
14th Dec 20237:00 amRNSMonthly Valuation Update, November Factsheet
6th Dec 20237:00 amRNSTransaction in Own Shares
1st Dec 20237:01 amRNSTotal Voting Rights
1st Dec 20237:00 amRNSTransaction in Own Shares
13th Nov 20237:00 amRNSPortfolio Company Update: CARGO Therapeutics, Inc
13th Nov 20237:00 amRNSTransaction in Own Shares
13th Nov 20237:00 amRNSMonthly Valuation Update, October Factsheet
9th Nov 20237:00 amRNSTransaction in Own Shares
8th Nov 20237:00 amRNSTransaction in Own Shares
1st Nov 202310:51 amEQSEdison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets
1st Nov 20237:06 amRNSRTW Biotech to acquire Arix Bioscience's assets
1st Nov 20237:05 amRNSTotal Voting Rights
16th Oct 20237:00 amRNSTransaction in Own Shares
13th Oct 20237:00 amRNSMonthly Valuation Update, Sep Factsheet, Q3 Letter
3rd Oct 20234:00 pmRNSDirector Declaration
2nd Oct 20237:00 amRNSTotal Voting Rights
18th Sep 20237:00 amRNSTransaction in Own Shares
15th Sep 20237:00 amRNSMonthly Valuation Update & August Factsheet
14th Sep 20237:00 amRNSUpdate on Largest Core Portfolio Position
13th Sep 20237:00 amRNSHalf-year Report
6th Sep 20237:00 amRNSTransaction in Own Shares
4th Sep 202311:00 amRNSAdditional Investment in Portfolio Company
14th Aug 20237:00 amRNSMonthly Valuation Update & July Factsheet
4th Aug 20237:30 amRNSEdison issues update on RTW Venture Fund (RTW)
1st Aug 202312:30 pmRNSTotal Voting Rights
21st Jul 20237:00 amRNSTransaction in Own Shares
17th Jul 20237:00 amRNSPortfolio Company Update: Apogee Therapeutics IPO
17th Jul 20237:00 amRNSMonthly Valuation Update, Factsheet & Q2 Letter
5th Jul 20237:00 amRNSCapital Allocation Plans from Prometheus Sale
30th Jun 202310:00 amRNSPortfolio Company Update: Tourmaline Bio
27th Jun 20237:00 amRNSChange of Name
21st Jun 20234:22 pmRNSResult of AGM
14th Jun 20237:00 amRNSMonthly Valuation Update & Factsheet
1st Jun 20237:00 amRNSNotice of AGM
12th May 20237:00 amRNSMonthly Valuation Update & Factsheet
9th May 20237:00 amRNSPortfolio Company Update: Acelyrin IPO
2nd May 20237:00 amRNSAnnual Financial Report
26th Apr 20237:00 amRNSNew Investment in Abdera Therapeutics
24th Apr 20232:39 pmRNSMarch Factsheet & First Quarter Letter
17th Apr 20237:00 amRNSPortfolio Company Update: Prometheus Biosciences
17th Apr 20237:00 amRNSMonthly Valuation Update
6th Apr 202312:00 pmRNSAppointment of Numis as Joint Broker
31st Mar 20235:20 pmRNSDirector/PDMR Shareholding
31st Mar 20237:00 amRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.